These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 26951556

  • 1. Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1.
    Lee J, Kim E, Ryu SW, Choi C, Choi K.
    J Neurooncol; 2016 May; 128(1):29-34. PubMed ID: 26951556
    [Abstract] [Full Text] [Related]

  • 2. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, Rey JA, Sunguroğlu A, Castresana JS, Ugur HC.
    Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
    Kohsaka S, Takahashi K, Wang L, Tanino M, Kimura T, Nishihara H, Tanaka S.
    Cancer Lett; 2013 Apr 30; 331(1):68-75. PubMed ID: 23246370
    [Abstract] [Full Text] [Related]

  • 4. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
    Lan F, Yang Y, Han J, Wu Q, Yu H, Yue X.
    Int J Oncol; 2016 Feb 30; 48(2):559-68. PubMed ID: 26648123
    [Abstract] [Full Text] [Related]

  • 5. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
    Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, Verhaak RG, Sulman EP, Kitange GJ, Sarkaria JN.
    J Natl Cancer Inst; 2016 May 30; 108(5):. PubMed ID: 26615020
    [Abstract] [Full Text] [Related]

  • 6. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
    Tian T, Mingyi M, Qiu X, Qiu Y.
    Oncotarget; 2016 Nov 29; 7(48):79584-79595. PubMed ID: 27792996
    [Abstract] [Full Text] [Related]

  • 7. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.
    Clin Cancer Res; 2014 Nov 15; 20(22):5756-67. PubMed ID: 25316808
    [Abstract] [Full Text] [Related]

  • 8. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.
    van Nifterik KA, van den Berg J, van der Meide WF, Ameziane N, Wedekind LE, Steenbergen RD, Leenstra S, Lafleur MV, Slotman BJ, Stalpers LJ, Sminia P.
    Br J Cancer; 2010 Jun 29; 103(1):29-35. PubMed ID: 20517307
    [Abstract] [Full Text] [Related]

  • 9. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H, Li J, Cheng G, Zhang J, Li X.
    Clin Neurol Neurosurg; 2016 Dec 29; 151():31-36. PubMed ID: 27764705
    [Abstract] [Full Text] [Related]

  • 10. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
    Clark PA, Gaal JT, Strebe JK, Pasch CA, Deming DA, Kuo JS, Robins HI.
    J Clin Neurosci; 2017 Feb 29; 36():120-124. PubMed ID: 27865821
    [Abstract] [Full Text] [Related]

  • 11. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
    Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, Guha A.
    J Clin Invest; 2012 Jan 29; 122(1):253-66. PubMed ID: 22156195
    [Abstract] [Full Text] [Related]

  • 12. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
    Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN.
    Neuro Oncol; 2009 Jun 29; 11(3):281-91. PubMed ID: 18952979
    [Abstract] [Full Text] [Related]

  • 13. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
    Perazzoli G, Prados J, Ortiz R, Caba O, Cabeza L, Berdasco M, Gónzalez B, Melguizo C.
    PLoS One; 2015 Jun 29; 10(10):e0140131. PubMed ID: 26447477
    [Abstract] [Full Text] [Related]

  • 14. Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
    Huang H, Lin H, Zhang X, Li J.
    Oncol Rep; 2012 Jun 29; 27(6):2050-6. PubMed ID: 22426504
    [Abstract] [Full Text] [Related]

  • 15. Neuropilin-1 enhances temozolomide resistance in glioblastoma via the STAT1/p53/p21 axis.
    Huang P, Zhang L, Wang H, Dou C, Ju H, Yue P, Ren J.
    Neuropathology; 2024 Aug 29; 44(4):319-330. PubMed ID: 38448392
    [Abstract] [Full Text] [Related]

  • 16. Olea europaea Leaf Extract Improves the Efficacy of Temozolomide Therapy by Inducing MGMT Methylation and Reducing P53 Expression in Glioblastoma.
    Tezcan G, Tunca B, Demirci H, Bekar A, Taskapilioglu MO, Kocaeli H, Egeli U, Cecener G, Tolunay S, Vatan O.
    Nutr Cancer; 2017 Aug 29; 69(6):873-880. PubMed ID: 28718668
    [Abstract] [Full Text] [Related]

  • 17. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W, DIRECTOR Study Group.
    Clin Cancer Res; 2015 May 01; 21(9):2057-64. PubMed ID: 25655102
    [Abstract] [Full Text] [Related]

  • 18. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.
    Neurosurg Focus; 2014 Dec 01; 37(6):E4. PubMed ID: 25434389
    [Abstract] [Full Text] [Related]

  • 19. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
    Happold C, Roth P, Wick W, Schmidt N, Florea AM, Silginer M, Reifenberger G, Weller M.
    J Neurochem; 2012 Jul 01; 122(2):444-55. PubMed ID: 22564186
    [Abstract] [Full Text] [Related]

  • 20. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.
    Pediatr Blood Cancer; 2007 Apr 01; 48(4):403-7. PubMed ID: 16609952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.